Cargando…
Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies
Antiphospholipid syndrome (APS) is an adquired autoimmune pro-thrombotic disease characterized by arterial and/or venous thrombosis and/or fetal losses associated with the persistent presence of antiphospholipid antibodies (aPL) detectable by solid phase assays (anticardiolipin (aCL) and anti-β2 gly...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698865/ https://www.ncbi.nlm.nih.gov/pubmed/31557999 http://dx.doi.org/10.3390/antib5030018 |
_version_ | 1783444631116054528 |
---|---|
author | Gómez-Puerta, José A. Espinosa, Gerard Cervera, Ricard |
author_facet | Gómez-Puerta, José A. Espinosa, Gerard Cervera, Ricard |
author_sort | Gómez-Puerta, José A. |
collection | PubMed |
description | Antiphospholipid syndrome (APS) is an adquired autoimmune pro-thrombotic disease characterized by arterial and/or venous thrombosis and/or fetal losses associated with the persistent presence of antiphospholipid antibodies (aPL) detectable by solid phase assays (anticardiolipin (aCL) and anti-β2 glycoprotein I, β2GPI) and/or functional coagulation test (lupus anticoagulant (LA)). Most patients with typical APS manifestations have the presence of one or more of conventional aPL, but, some patients might exhibit clinical features related with APS but with persistent negative determinations of “classic” aPL (seronegative APS). Expanding the network of autoantibodies in patients highly suspected of having APS but who have normal results from a conventional test using new antibodies (i.e., phosphatidylserine/prothrombin and β2GPI domain 1) would increase the diagnosis. Thrombosis is one of the leading causes of death among patients with cancer, representing up to 15% of all deaths. Cancer increases the risk of thrombosis and chemotherapy is further associated with a higher risk of thrombosis. In addition, aPL may contribute to an increased risk of thrombosis in patients with malignancies, although the levels do not seem to reflect their pathogenicity. Several malignancies, particularly hematological and lymphoproliferative malignancies, may indeed be associated with the generation of aPL but do not necessarily enhance the thrombophilic risk in these patients. |
format | Online Article Text |
id | pubmed-6698865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66988652019-09-05 Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies Gómez-Puerta, José A. Espinosa, Gerard Cervera, Ricard Antibodies (Basel) Review Antiphospholipid syndrome (APS) is an adquired autoimmune pro-thrombotic disease characterized by arterial and/or venous thrombosis and/or fetal losses associated with the persistent presence of antiphospholipid antibodies (aPL) detectable by solid phase assays (anticardiolipin (aCL) and anti-β2 glycoprotein I, β2GPI) and/or functional coagulation test (lupus anticoagulant (LA)). Most patients with typical APS manifestations have the presence of one or more of conventional aPL, but, some patients might exhibit clinical features related with APS but with persistent negative determinations of “classic” aPL (seronegative APS). Expanding the network of autoantibodies in patients highly suspected of having APS but who have normal results from a conventional test using new antibodies (i.e., phosphatidylserine/prothrombin and β2GPI domain 1) would increase the diagnosis. Thrombosis is one of the leading causes of death among patients with cancer, representing up to 15% of all deaths. Cancer increases the risk of thrombosis and chemotherapy is further associated with a higher risk of thrombosis. In addition, aPL may contribute to an increased risk of thrombosis in patients with malignancies, although the levels do not seem to reflect their pathogenicity. Several malignancies, particularly hematological and lymphoproliferative malignancies, may indeed be associated with the generation of aPL but do not necessarily enhance the thrombophilic risk in these patients. MDPI 2016-08-02 /pmc/articles/PMC6698865/ /pubmed/31557999 http://dx.doi.org/10.3390/antib5030018 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gómez-Puerta, José A. Espinosa, Gerard Cervera, Ricard Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies |
title | Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies |
title_full | Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies |
title_fullStr | Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies |
title_full_unstemmed | Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies |
title_short | Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies |
title_sort | antiphospholipid antibodies: from general concepts to its relation with malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698865/ https://www.ncbi.nlm.nih.gov/pubmed/31557999 http://dx.doi.org/10.3390/antib5030018 |
work_keys_str_mv | AT gomezpuertajosea antiphospholipidantibodiesfromgeneralconceptstoitsrelationwithmalignancies AT espinosagerard antiphospholipidantibodiesfromgeneralconceptstoitsrelationwithmalignancies AT cerveraricard antiphospholipidantibodiesfromgeneralconceptstoitsrelationwithmalignancies |